UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Aurobindo Pharma USA Inc. Petitioners,

v.

Andrx Labs, LLC Patent Owner

Case IPR2017-01648 U.S. Patent No. 6,866,866

&

Case IPR2017-01673 U.S. Patent No. 6,790,459

PATENT OWNER'S MANDATORY NOTICES UNDER 37 C.F.R. § 42.8



PATENT OWNER MANDATORY NOTICES

Pursuant to 37 C.F.R. § 42.8, Patent Owner Andrx Labs, LLC, respectfully submits the following Mandatory Notices.

I. REAL PARTY IN INTEREST

Based on the Patent Owner's current understanding, the real parties-in-interest ("RPI") are Andrx Labs, LLC, Teva Pharmaceuticals USA Inc., and Shionogi Inc. The Patent Owner continues its investigation regarding entities which should be named as RPIs and will update these Mandatory Notices if and as needed.

II. RELATED MATTERS

Patent Owner identifies the following U.S. patent applications and issued patents that relate to U.S. Patent Application No. 09/705,630, which issued as U.S. Patent No. 6,866,866:

- U.S. Patent Application No. 09/705,630, which was filed on November 3, 2000, and issued as U.S. Patent No. 6,866,866;
- U.S. Patent Application No. 10/796,411, which was filed on March 9, 2004, and is now abandoned;



- U.S. Patent Application No. 11/117,999, which was filed on April 29, 2005, and is now abandoned;
- U.S. Patent Application No. 11/225,741, which was filed on September 13, 205, and is now abandoned;
- U.S. Patent Application No. 11/225,742, which was filed on September 13, 205, and is now abandoned;
- U.S. Patent Application No. 11/225,784, which was filed on September 13, 205, and is now abandoned; and
- U.S. Patent Application No. 11/225,785, which was filed on September 13, 205, and is now abandoned.

Patent Owner is unaware of any U.S. patent applications and issued patents that relate to U.S. Patent Application No. 09/705,625, which issued as U.S. Patent No. 6,790,459.



Additionally, Patent Owner identifies the following matters that relate or may relate to U.S. Patent Application No. 09/705,630, which issued as U.S. Patent No. 6,866,866 and U.S. Patent Application No. 09/705,625, which issued as U.S. Patent No. 6,790,459:

- U.S. Patent No. 6,866,866 was a patent-in-suit in *Sciele Pharma Inc.* et al. v. Lupin Ltd., et al., 1:09-cv-00037 (D. Del. Jan. 15, 2009), which is now closed;
- U.S. Patent No. 6,866,866 and U.S. Patent No. 6,790,459 were patents-in-suit in *Sciele Pharma, Inc. et al v. Lupin Ltd. et al.*, No. 1-09-cv-00105 (D. Md. Jan. 16, 2009), which is now closed;
- U.S. Patent No. 6,866,866 was a patent-in-suit in *Shionogi Pharma*Inc. et al. v. Mylan Inc., et al., 1:10-cv-00135 (D. Del. Feb. 18, 2010),
 which is now closed;
- U.S. Patent No. 6,866,866 and U.S. Patent No. 6,790,459 were patents-in-suit in *Takeda Pharmaceutical Company Limited et al v. Mylan, Inc. et al.*, No. 1-12-cv-00024 (S.D. N.Y. Jan. 3, 2012), which is now closed;
- U.S. Patent No. 6,866,866 and U.S. Patent No. 6,790,459 were patents-in-suit in *Takeda Pharmaceutical Co., Ltd., et. al. v. Mylan,*



Inc., et. al., No. 2-12-cv-00026 (W.D. Pa. Jan. 6, 2012), which is now closed;

- U.S. Patent No. 6,866,866 and U.S. Patent No. 6,790,459 were patents-in-suit in *Takeda Pharmaceutical Company Limited et al v. Mylan, Inc. et al.*, No. 1-12-cv-02038 (S.D. N.Y. Mar. 20, 2012), which is now closed;
- U.S. Patent No. 6,866,866 was a patent-in-suit in *Sciele Pharma Inc.* et al. v. Lupin Ltd., et al., No. 2012-1228 (Fed. Cir. July 2, 2012), which is now closed;
- U.S. Patent No. 6,866,866 was a patent-in-suit in *Shionogi Inc. et al.*v. Nostrum Laboratories, Inc., et al., 1:12-cv-04402 (D. N.J. July 13, 2012), which is now closed; and
- U.S. Patent No. 6,866,866 and U.S. Patent No. 6,790,459 were patents-in-suit in *Shionogi Inc. and Andrx Labs. L.L.C. v. Aurobindo Pharma Ltd. et al.*, Civ. Act. No. 1:17-cv-00072-UNA (D. Del. Jan. 25, 2017), which remains pending.

III. COUNSEL

Lead Counsel:

David L. Cavanaugh, Reg. No. 36,476



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

